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We propose a framework for understanding and interpreting the pathophysiology
of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) that considers
wider determinants of health and long-term temporal variation in pathophysiological
features and disease phenotype throughout the natural history of the disease. As in
other chronic diseases, ME/CFS evolves through different stages, from asymptomatic
predisposition, progressing to a prodromal stage, and then to symptomatic disease.
Disease incidence depends on genetic makeup and environment factors, the exposure
to singular or repeated insults, and the nature of the host response. In people
who develop ME/CFS, normal homeostatic processes in response to adverse insults
may be replaced by aberrant responses leading to dysfunctional states. Thus, the
predominantly neuro-immune manifestations, underlined by a hyper-metabolic state,
that characterize early disease, may be followed by various processes leading to
multi-systemic abnormalities and related symptoms. This abnormal state and the effects
of a range of mediators such as products of oxidative and nitrosamine stress, may
lead to progressive cell and metabolic dysfunction culminating in a hypometabolic
state with low energy production. These processes do not seem to happen uniformly;
although a spiraling of progressive inter-related and self-sustaining abnormalities may
ensue, reversion to states of milder abnormalities is possible if the host is able to
restate responses to improve homeostatic equilibrium. With time variation in disease
presentation, no single ME/CFS case description, set of diagnostic criteria, or molecular
feature is currently representative of all patients at different disease stages. While
acknowledging its limitations due to the incomplete research evidence, we suggest the
proposed framework may support future research design and health care interventions
for people with ME/CFS.
Keywords: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Chronic Fatigue Syndrome, ME/CFS, chronic
illness, management, research
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INTRODUCTION
The lack of progress in Myalgic Encephalomyelitis/Chronic
Fatigue Syndrome (ME/CFS) research has been attributed to a
range of factors, including the paucity of large, high quality,
hypothesis-driven studies, and controversy around diagnosis.
Without recognized and validated biomarkers or diagnostic tests,
there is an over-reliance on patient history for diagnosis, which
is based on criteria with limited sensitivity and specificity (1)
and which ignore disease sub-groups. Furthermore, the lack
of consistency in the choice and application of research case
definition has led to problems with reliability and comparability
of research findings (2). An additional factor complicating
diagnosis and case definition for research studies is the time-
related variation in phenotype both in the short- (3, 4) and long-
term (5), which has seldom been considered in research studies.
In addition to oftenmarked variability in disease presentation,
severity, progression, and duration among different individuals,
the way disease manifests in each individual may change with
time. Inter- and intra-individual phenotypic variations lend
toward the categorization of different subtype trajectories of
ME/CFS that may differ in pathogenesis and prognosis. In
some studies, female sex, increased age (6–8), and lower socio-
economic status (9) have been found to predict poor prognosis;
however, the variable nature of both population sampling
and diagnostic criteria has led to ambiguous results and has
reinforced the need for ongoing research in this area (10). Further
subtypes have been defined on the basis of “minor” symptoms
i.e., musculoskeletal, infectious, or neurological (11), through
genetic studies (12, 13), metabolomics studies (14), and, duration
of disease studies (5), highlighting the multitude of possible
ways ME/CFS patients can be categorized. Other studies have
identified variations in symptom profiles as disease progresses;
however, such results are often limited by cross-sectional study
design (15), and/or recall bias (16). The breadth of subtype
studies available follow a similar model of looking for patterns
across patient groups at single time-points; far fewer consider
longitudinal subtyping and disease progression of a single patient
cohort over time.
The concept of the natural history of disease is well-
understood in public health and medicine: many, if not all,
diseases are framed using this construct to formulate how they
progress from a pre-illness stage to a final disease outcome, which
may vary from full recovery to death. A good understanding of
the disease course is vital not only for the design of preventative
and intervention studies (17), but also to assess the timing and
type of intervention that minimizes disease risk or optimizes
prognosis. Although there is some understanding of the natural
history of ME/CFS, this has been limited by problems in case
definition (as above) as well as by the paucity of longitudinal
studies, and in particular those that follow up individuals’ pre-
illness. A review of studies on CFS prognosis (8) suggested
recovery rates under 10% in adults, and an improvement rate
over 40% for people with fatigue lasting <6 months. The
prognosis was worse: when more stringent case definitions were
used; in older people; in cases with more severe symptoms;
and, in the presence of psychiatric co-morbidity. A subsequent
systematic review on prognosis found a median recovery rate of
5%, and median proportion of people improving of 39.5% (18)
with most reporting symptoms still present at follow-up.
This conceptual paper explores the long-term course
of ME/CFS and how presentation and pathophysiological
abnormalities may vary with time. The pathophysiological
concepts discussed are based on evidence from clinical
observations and research, where available, and, as such, are not
claimed to be original or indeed conclusive. Instead, they serve
to highlight our proposed characterization of ME/CFS’s distinct
stages within the framework of the natural history of the disease.
PATHOPHYSIOLOGICAL AND CELLULAR
ABNORMALITIES FOLLOWING HOST
EXPOSURE TO “INSULTS” OR
“STRESSORS”
Prior to exploring the course of ME/CFS, we propose to revisit
some concepts related to mechanisms of disease that have
been used in the context of life-threatening emergencies and
to potential return to homeostasis, such as those occurring
in sepsis or poly-trauma. Although very different to ME/CFS,
these acute injuries have been extensively studied, and the
high intensity and speed of events result in changes that are
easily identified and well-described, from potential homeostatic
failure to recovery. We present the following models as a
paradigm for the understanding of disease mechanisms, based
on well-studied examples. They merely serve as a reference
for mechanisms that the host may partially engage with
in the presence of insults of different severities. Hence, in
the following paragraphs, we explore the pathophysiological
mechanisms that may be taking place in ME/CFS, which have
been related to abnormal homeostasis guided by these established
disease descriptions.
The response to an insult frequently involves multiple body-
systems and has components that are independent of the etiology
of the insult and, to some extent, its severity. There are many
commonalities between the response to sepsis and to poly-
trauma: both are acute and severe insults, to which many of the
aspects of the host response are indistinguishable. Our proposal
is based on the idea that there may be some similar mechanisms
at play when individuals predisposed to ME/CFS are faced with
a range of “insults” or “stressors.” Needless to say, the hyper-
acute changes and co-factors in both sepsis and poly-trauma
occur in very rapid sequence, whereas in ME/CFS, physiological
changes, even if they resemble those of acute injury in some
respects, take place at a much slower pace with less obvious and
uniform patterns.
Non-specific Changes in Response to
Severe Acute Injury
In both sepsis (19) and poly-trauma, (20, 21) a state of hyper-
inflammation is observed initially as the host responds to
the infection or traumatic stress with marked production of
pro-inflammatory mediators, e.g., cytokines and polypeptides.
A failing circulatory system is associated with activation of
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the hypothalamic-pituitary-adrenal (HPA) axis and increased
sympathetic drive, contributing to metabolic changes and to
increased energy expenditure (22, 23).
In these conditions, the acute pro-inflammatory state is
usually followed by a compensatory anti-inflammatory response,
with a different profile of biochemical and molecular mediators.
The success of the host in balancing pro- with anti- inflammatory
responses alongside injury-related factors, are key to improved
long-term outcomes. The direct and indirect effects of immune
cells and active products derived from immune, neural, and
endocrine systems (some of which cause pathology if present
in excess) contribute to a number of physiological changes,
including those leading to the formation of reactive oxygen
species (ROS, oxidative stress) and reactive nitrogen species
(RNS, nitrosative stress). Endothelial and parenchymal (organ)
cell damage may result because of a combination of factors,
such as polymorphonuclear leukocyte infiltration and the action
of reactive oxygen and nitrogen species, cytokines, vasoactive
amines, and other products. Endothelial dysfunction results in
capillary leakage, accelerated inflammation, platelet aggregation,
coagulation, and loss of vascular tone (24). Vascular dysfunction
is associated to peripheral vasodilation due to increased nitric
oxide and prostacyclin synthesis (25) and to a decrease in
the proportion of perfused vessels and an increase in the
heterogeneity of blood flow distribution (26). This results
in relative hypovolemia, decreased capillary flow, haemo-
concentration, and micro-thrombi formation, and further
contributes to reduced exchanges of oxygen and nutrients at the
microcirculatory level. The consequent decreased cellular oxygen
delivery eventually leads to cytopathic hypoxia. Adenosine
triphosphate (ATP) increased consumption and ensuing deficits
cascade into a range of metabolic disturbances with systemic
effects (27), and promote changes in membrane permeability
that lead to dysfunctional transmembrane ion transport. In
acutely and severely ill patients, reperfusion results in further
oxidative damage (22, 28). Additional failures of biological and
cell processes lead to multiple dysfunction, to system and organ
failure, and to potentially irreversible disease (22).
Evidence of Abnormalities in ME/CFS and
Loss of Normal Homeostasis
Concepts that are relevant here are those of homeostasis
and allostasis. While homeostasis refers to the “stability of
physiological systems,” allostasis has been defined as “the adaptive
processes aimed to maintain homeostasis following acute stress,
and which contribute to wear and tear on the body and the
brain, or allostatic overload” (29). A central characteristic of
individuals with ME/CFS points to a state of homeostatic
failure (30), aggravated by the incidence of, or increase in,
levels of new stressors or by the increase in allostatic load
(31). Typical stressors include infection [(32): 17–21], physical
exertion and cognitive effort (e.g., reading or solving mental
puzzles) triggering post-exertional malaise (PEM) (33), comorbid
conditions (e.g., sleep disturbances) (34) and a range of
environmental and individual factors (35–40).
In those who do not develop ME/CFS or prolonged illness
following an insult such as an acute infection, external stressors
may initially cause physiological changes accompanied by non-
specific symptoms, but the state of homeostatic equilibrium
that operated before the insult is quickly restored. Failing re-
establishment of this equilibrium, there may be a shift to a state of
“aberrant homeostasis,” where physiological processes converge
to a new or alternative state of functioning; a state that remains
homeostatic in nature, but functions at a less optimum level
(41). While such a state may be adequate for many physiological
processes, it will be inadequate or inefficient for a number of
other processes and functions and the prolongation of such
aberrant functioning will represent another potential source of
ongoing stress.
There is a growing body of evidence on biological
abnormalities in ME/CFS that has been reviewed elsewhere
(32, 42, 43), and summarized by Komaroff (44). Of note,
many of the abnormalities shown in severe injury have also
been identified in ME/CFS such as: immune dysfunction,
including pro-inflammatory response (especially at early stages
of disease) (45, 46); autonomic nervous system (47–49); HPA axis
dysfunction (50); hypovolemia (51); nitrosamine and oxidative
stress (52); endothelial dysfunction (52); metabolic dysfunction
(53–55); dysfunction of membrane transport (56); and, tissue
hypoxia (57).
THE STAGES OF ME/CFS
Other tools widely used in clinical medicine are staging systems.
Using sepsis again as an example, such a system was proposed
at the International Sepsis Definitions Conference in 2001
to introduce the stratification of patients with sepsis (58).
By applying PIRO (predisposition, infection/insult, response,
and organ dysfunction) patients are stratified into appropriate
subgroups allowing for more accurate prognostication in
emergency medical services (59). The idea of classifying people
with ME or CFS into distinct categories or stages has been
explored previously by several theorists. One school of thought
proposes categories based on the psychological process of coming
to terms with this new and evolving state of health rather than
addressing biological differences, and are defined as such by the
emotions common to any trauma experience: e.g., denial, fear,
frustration, and acceptance (60, 61). Alternatively, Schweitzer
(62) proposes the different presentations of CFS according to
more physical categories (Prodrome, Relapse and Remission,
Improvement and Plateau, and Collapse followed by slow
worsening with no remission); it is these that we aim to expand
on, as follows.
We show a tentative representation of the key
pathophysiological mechanisms operating in each stage of
ME/CFS in Figure 1. As in severe injury or sepsis, the range
and order of occurrence of biological processes taking place
in ME/CFS may vary, as may their relative significance
and impact on each individual. Therefore, it is important
to note that although the various abnormalities may occur
continuously and often simultaneously, the predominance of
Frontiers in Neurology | www.frontiersin.org 3 August 2020 | Volume 11 | Article 826
Nacul et al. The Natural History of ME/CFS
FIGURE 1 | Hypothesized key pathophysiological mechanisms for ME/CFS.
specific dysfunctions varies over time and from individual
to individual.
Furthermore, we propose a characterization of disease stages
in ME/CFS, based on the natural history of disease framework
considering available descriptions from the literature (32),
and the life-stories reported by our own cohort of research
participants with ME/CFS (including those with mild/moderate
or severe symptoms) (63). This characterization is summarized
in Table 1, which may be used in support of research designs that
consider the disease presentation in distinct phases.
Predisposition and Triggering of Disease
Individuals with a combination of genetic predispositions and
exposures to environmental factors may first manifest symptoms
of ME/CFS following their encounter with a specific trigger,
of which acute infections of various etiologies are the most
commonly reported (64, 65); other patients report a more
insidious onset with no obvious initiating factor (32). While
it remains unclear exactly which individuals are predisposed
to develop ME/CFS and why, some patterns have emerged.
For example, gender- and age-specific factors are thought to
contribute to the risk of ME/CFS (66), with epidemiological
studies consistently reporting higher rates of the disease in
females (67, 68). Although most cases are endemic, there have
been reports of epidemic cases, suggesting an infectious or
other environmental cause play a role (43, 69–72); although
discrepancies in onset patterns and case definitions make these
epidemics difficult to compare (72). Many studies have reported
an association between acute viral infection and the development
of ME/CFS (73–76). Cases are predominantly reported in North
America, Europe, and Oceania; however, the occurrence of
ME/CFS is thought to be global with evidence of cases in other
parts of the world (77–79).
Psychiatric morbidity, experiences of stress and trauma, either
physical or emotional have been reported to precipitate the
disease (16, 80–82) and to predict disease progression (83),
under the explanatory biopsychosocial models. However, these
models have not been replicated (84, 85). Furthermore, Chu
et al. (16) found that even when a significant proportion of
their research population report stress or a major life event as
a precipitating factor for ME/CFS, “stressful events were rarely
chosen as the only precipitant though, endorsed only by 8% of
our subjects, and appeared mostly in conjunction with infection
or other precipitants.” We acknowledge that stress may play a
role in the development and perpetuation of ME/CFS through
its role on the immune system and HPA axis dysfunction (86), or
by aiding transmission or reactivation of viral infections (87), or
as a consequence of the loss of normal functioning experienced
by the individual.
The role of genetic variation has been supported by a
number of family-based studies assessing the possibility of a
heritable component (88–90). Genes underpinning immune
system function and inflammatory response may contribute
to genetic susceptibility for ME/CFS; some studies suggest
associations with human leucocyte antigen class II alleles (91, 92)
and in genes related to the complement cascade, chemokines,
cytokine signaling, and toll-like receptor signaling (93). Small
genome-wide association studies (GWAS) have had little overlap
in results save for two SNPs in the GRIK2 gene: a gene implicated
in a number of neurological conditions such as autism and
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TABLE 1 | Proposed characterization of disease stages in an individual with ME/CFS, within the framework of natural history of diseases.
Timing No disease Onset 0–4 months¶ 4–24 months* 2 years +
†
Stage Predisposition Trigger and pre-illness Prodromal period Early disease Established disease
Clinical phenotype No symptoms Non-specific or related to
triggering “insult”
Fatigue-complex
symptoms‡
Fatigue-complex
symptoms‡ variable severity
and progress
Mild, moderate, severe
and complicated
disease
Prevention level¶ Primary prevention Treatment of “insult” and
primary prevention
Secondary prevention Treatment and secondary
prevention
Treatment and tertiary
prevention
Recovery Potential§ Likely Possible Less likely
Pathophysiology Predisposing factors Non-specific host
response and related to
specific trigger factor
Neuro-immune response to
insult and fight for
homeostasis
Neuro-inflammation and
systemic consequences;
aberrant homeostasis
Systemic disease,
aberrant or failed
homeostasis
*3–6 months is commonly proposed as the minimum period of symptoms before diagnosis is made in children and adults, respectively (32).
†
2 years has been used as a cut off to distinguish between short and long term duration of disease (94, 95), but its use as defining established disease is variable and depends on a
range of factors, including individual response to early disease.
‡Fatigue-complex symptoms: initially predominantly neuro-immune (prior to early disease), and variable systemic symptoms in established disease.
§Tentative proportions for recovery are: likely (>75%); possible (<20%); less likely (<5%). “Likely” and “possible” are based on recovery from arboviruses and EBV [(96); 100]; “less likely”
is based on reviews on prognosis (97).
¶The Prevention level will be considered further in a subsequent publication which is being prepared by the authors.
schizophrenia (98); in the GRIK3 gene: relating to a pattern
recognition receptor capable of binding to a broad range of
pathogens; and in the non-coding regions of T-cell receptor loci
(99). A further study reported SNP markers in candidate genes
involved in HPA axis function and neurotransmitter systems that
distinguished individuals with ME/CFS (100).
Prodromal Period
It is important to preface here that, with the current diagnostic
methodology of ME/CFS stipulating the presence of symptoms
for more than 6 months (101, 102) and the absence of a positive
validated diagnostic test, the following processes (occurring pre-
diagnosis) are difficult to substantiate from existing biomedical
research. However, based on the published work on ME/CFS and
considering the pathophysiological events happening in sepsis
and polytrauma may be similar (though in a much slower pace),
we hypothesize that the following may occur.
In addition to any manifestations specifically related to the
acute insult or triggering event, the mechanisms involved in
producing the first symptoms of ME/CFS may be similar to what
has been described in relation to “sickness behavior” (103) or
in those with severe acute disease, i.e., “systemic inflammatory
response syndrome” (19). These result from the interaction of an
infective agent or other insult with the host’s immune system, as
well as their potential effect on the host’s central nervous system
(CNS). The immune system-nervous system interactions involve
bidirectional signals (104–106): while immune system activity
may interfere with CNS function via various mechanisms, e.g.,
release and action of pro-inflammatory cytokines and other
mediators, various neurotransmitters, neuropeptides, and neuro-
hormones may also affect immune function. Additionally, the
HPA system and the autonomic nervous system (ANS) are
affected, with consequences that may be observed well-beyond
the CNS. These effects may vary according to different factors,
such as host susceptibility, the nature and persistence (or return
to normality) of systemic and local immune dysfunction, altered
CNS metabolism, neuro-transmission, brain perfusion changes,
and the integrity of the blood-brain barrier (107–110).
Particular characteristics of the specific infectious agent or
stressor may also play a role during this prodromal stage,
which would explain the different risks of disease development
following acute infection. For example, there has long been an
interest in the association between ME/CFS and infections such
as Epstein-Barr virus (EBV) and other herpesviruses (73, 111–
116). Herpesviruses tend to be neurotropic and persist following
acute infection in a latent state. Similar to EBV infection (117),
the risk of chronic fatigue has been shown to be substantially
increased following viral meningitis, a relatively severe infection
of the CNS (83).
Early Disease
Early disease represents a continuation of the processes initiated
at the prodromal period, when there is a failure of physiological
and homeostatic processes to resume previous levels of
equilibrium and normality. Fatigue and other symptoms may
be largely explained by a combination of the local and systemic
effects of pro-inflammatory and other mediators or toxins, CNS
metabolic dysfunction (with enhanced excitability and other
changes), and a systemic hyper-metabolic state. With higher
energy demands for essential biological processes, there will be a
reduction in the available energy for less essential tasks, including
those demanding increased physical or mental exertion. The
increased production and action of anti-inflammatorymediators,
as well as their ability to counter-balance pro-inflammatory
stimuli, modulate physiological responses, and symptoms
and affect disease progression or reversibility. As mentioned
previously, without a validated biomarker to diagnose ME/CFS
early it is difficult to substantiate the exact mechanisms occurring
in the early disease phase. Research into potential diagnostic
markers, such as the recent study on impedance signatures (118),
are crucial not only clinically, but to identify these mechanisms
as possible targets for early intervention.
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Established ME/CFS
The persistence of immune and CNS dysfunction with the initial
over-production of pro-inflammatory and neurotoxic factors
may result in a prolonged state of low-grade neurological
and systemic inflammation. In the CNS, a status of glial
activation with microglial hypersensitivity to peripheral (119)
and regional stimuli is established (104, 119–121), akin to what
has been described in chronic pain states (122). In support
of CNS dysfunction, neuroimaging studies have shown various
abnormalities in ME/CFS, often associated with symptoms of
fatigue and other indications of severity (123). Glial activation in
several areas of the brain has also been demonstrated in positron
emission tomography (PET) scans of patients with fibromyalgia
(FM), compared to controls, which was correlated to the
severity of fatigue (123, 124). Neuro-glial bidirectional signaling
is associated with increased production of neuro-excitatory
neurotransmitters and immune-inflammatory mediators (120).
Nervous system dysfunction affecting parts of the brain, brain
stem, and ANS, could explain not only the encephalopathic
or neuro-cognitive type of symptoms, but also those resulting
from disruption of key central regulatory mechanisms, such
as those involved in endocrine, circulatory, thermoregulation,
and respiratory control (16, 32, 48, 120, 125). Examples of
these include intolerance to extremes of temperature, chills and
temperature variations, intolerance to exertion, hyperventilation
or irregular breathing, orthostatic intolerance, with hypotension
or postural orthostatic tachycardia, and other symptoms related
to autonomic and endocrine control function (102).
Among the various by-products produced as a consequence
of ongoing abnormalities, are highly ROS and nitric oxide
synthase (NOS) or free radicals, which affect cell signaling and
cell functioning and structure, particularly when present at high
levels. It has been hypothesized that free radicals, and increased
levels of nitric oxide and peroxynitrite in particular, play a
significant role in ME/CFS (126, 127); their links to immune
and neuro signaling, cell integrity, mitochondrial function, and
energy metabolism may play an important part in the long term
abnormalities in ME/CFS.
The nature of neuro-immune and other dysfunctions may
change as disease progresses. While a pro-inflammatory state is
typical of the early response to insults, immune abnormalities
may become less marked (and less pro-inflammatory) with time
(128), and patients with longer periods of illness may show
fewer inflammatory immunological abnormalities. In support
of this, our preliminary results from the analysis of over 200
ME/CFS patients participating in the UK ME/CFS Biobank
(UKMEB), showed that the reported time since disease onset
was significantly associated with 2 cytokines, namely SCD40L
and IL1RA (manuscript in preparation). These results were
found after aliquots of peripheral blood mononuclear cells
(PBMC) from participants were stimulated (i.e., subjected to an
infection resembling stimulus) and analyzed with MAGPIX R©
multiplexing system. The statistical analyses were conducted
after transforming each cytokine measurement to the logarithm
scale to approximate normality; linear regression of these log-
transformed values (adapted for truncated outcome variables to
account for the assay’s limits of detections) was applied to the
variables’ time since onset, level of severity (mild to moderate
vs. severe) and the interaction between severity and time since
onset, while also adjusting for age and sex. The results evidenced
a decrease of sCD40L—a pro-inflammatory cytokine—and an
increase of IL1RA—an anti-inflammatory cytokine—for every
additional year since onset of ME.
Long-Term, Advanced, and Complicated
Disease
As the disease progresses, physiological, and systems
abnormalities take their toll and cell dysfunction becomes more
pronounced. Endothelial dysfunction may arise as a consequence
of a range of factors, including, but not limited to, persistent
oxidative and nitrosative stress and circulatory dysfunction
(43, 52, 126, 129, 130). The associated reduced delivery of
oxygen and nutrients to the cell leads to a deterioration of cell
function and impaired energy metabolism (129, 131, 132) and
a decreased ability of the cell to extract oxygen and produce
energy, a condition known as cytopathic hypoxia. As suggested
by Naviaux et al. (54), in cases of ME/CFS with mean duration
of symptoms over 17 years, there is a shutting down of various
metabolic processes leading to a hypometabolic state, i.e., a move
to an energy-saving mode. At this stage, symptoms are likely to
be severe, with profound fatigue, intolerance to effort, PEM and
other systemic symptoms, which are largely explained by the
slowness of physiological and metabolic processes and decreased
energy production.
DISCUSSION
Disease Severity and Reversibility
It is unknown how the initial host response to a stressor or
insult compares in individuals who do or do not develop typical
symptoms of ME/CFS. However, the return to good health,
which happens to most people following exposure to mild or
moderate levels of insult, seems to be impeded in ME/CFS when
symptoms persist for longer than 3–6 months; the time interval
that is featured in some of the currently used diagnostic criteria
(2, 101, 102). This suggests that subsequent mechanisms involved
in the host response will differ at some point in those who develop
ME/CFS from those who regain full health. Therefore, a key
question is what determines full recovery? Or alternatively, what
determines the perpetuation and transformation of symptoms?
While the abnormalities observed in acute disease are general
and mostly reversible once the challenge from the stressor ceases,
some degree of dysfunction may persist for longer periods. The
degree of reversibility of various physiological abnormalities is
likely to decrease with time, and some permanent functional, and
even structural, damage may occur consequently. This is likely
caused by either the persistence or frequent reactivation of the
initial stressor (87, 133), an accumulation of insults, a continuing
dysfunctional host-response, or the effects of the numerous
psychosocial risk factors that influence disease development and
progression (134), or a combination of all of these.
Although our framework focuses on the underlying biological
mechanisms that may be at play in the development and
progression of ME/CFS, it is important to acknowledge the
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impact of psychosocial and behavioral aspects in the progression
of chronic diseases. Stressors such as stressful life events, low
satisfaction with social and medical support, and excessive
use of coping mechanisms, have been shown to contribute to
the neuroendocrine and immune responses by acting through
complex pathways that ultimately affect health and health
outcomes (134–136).
The interplay between these three dimensions (biological,
psychosocial, and behavior) has been noted in the development
and the progression of a number of chronic diseases and to
influence disease outcomes (136–139). The combined effects
of stress from work or family life, social deprivation, and
depression have been found to contribute to the risk of
cardiovascular diseases, including coronary heart disease (140)
and myocardial infarction (141), and to a worse prognosis
(142) by enhancing cortisol secretion, increasing sympathetic
activation, and elevating plasma catecholamine levels (143). A
higher cumulative average number of stressful life events, when
coping involves denial, and higher levels of serum cortisol
have been found to be associated with a faster progression to
AIDS (144). Correspondingly, low stress levels and low scores
of avoidance coping behaviors were shown to be protective
against relapse in Crohn’s disease patients (135) in contrast to
high levels, which act as mediators, overloading the sympathetic
nervous system.
In the case of ME/CFS, the effect of these dimensions is
the same. In fact, one framework has been used to propose
a model for managing patients with this disease in which
it is considered that genes predispose, life events precipitate,
and behaviors perpetuate (145–147). However, this model may
downplay the important role of the biological mechanisms
involved in ME/CFS and overstate the role of psychosocial and
behavioral factors (148).
The pathophysiological distinction between cases from the
milder to the more severe end of the ME/CFS spectrum may
relate to near-normal homeostatic regulation in milder cases, and
established “aberrant homeostasis” or homeostatic dysregulation
with multi-systemic consequences in moderate to severe
cases. Alternatively, homeostatic failure, along with variable
multi-system physiological failure and increasing degrees of
irreversibility, may happen in the most severe cases.
The early stage of ME/CFS is of variable duration but is
usually considered to be between 4 and 6 months to 2 years
after the start of prodromal symptoms. Reversibility is possible,
but often people will evolve to chronicity or established ME/CFS
with either: (a) partial reversal of dysfunctional physiological
mechanisms (mild cases with slow improvement over time); (b)
persistence of dysfunctions and symptoms (mild or moderate
cases with stable symptoms or slow changes over time); or (c)
worsening dysfunctions and symptoms (moderate and severe
cases) (149). Note that some cases present early with severe
symptoms, which not uncommonly evolve to a milder form
(150). The use of coping mechanisms, such as pacing, can
also help improve energy management in people with ME/CFS
over time and reduce the risk of relapse into a more severe
state; however, there is little evidence that these will lead to
a reversibility (151). There is some indication that rates of
resolution are higher in cases of epidemic CFS compared to
sporadic cases, although very few of these individuals will recover
to their pre-morbid level (152).
One way of thinking about these phases is as interconnected
spirals, each representing a distinct disease phase. Individuals
may either remain for long periods in a single phase with
symptoms fluctuating within the “spiral section” or move
between phases either upwards (i.e., toward better health status)
or downwards (i.e., toward disease deterioration). Figure 2
represents an illustration of the multi-spiraling disease course
suggested for ME/CFS, and shows how patients may move across
spirals, with different molecular and system abnormalities.
Common Comorbidities in ME/CFS
There are a number of comorbid conditions associated with
ME/CFS and, as such, these comorbidities can complicate
diagnosis, treatment and research of the disease. Comorbidities
have been found in up to 97% of people with ME/CFS (PWME)
(16, 153) with some developing before, with, or after ME/CFS
onset (102). The complexity of ME/CFS is in part due to the
number of different systems affected that contribute to the many
and varied symptoms experienced. ME/CFS and FM share a
number of overlapping core symptoms that mean the two are
commonly experienced together; FM has been reported to co-
occur in 12–91% of PWME (16, 154, 155). However, there is
evidence to suggest the two conditions differ in their hormone
dynamics, genetic/molecular biology, and autonomic function
(156, 157). This is reiterated by the absence of post-exertional
malaise in FM (158, 159), which is one of the key features of
ME/CFS (2, 101, 102, 160).
Sleep disturbances can cause some symptoms that are also
present in ME/CFS including fatigue, joint pain, and impaired
cognition (161–165). Additionally, as part of a bidirectional
relationship, comorbid pain conditions may further impact sleep
quality (34). Sleep disturbances are also present in a number of
neurological diseases (166), which would explain their presence
as an important feature in ME/CFS (2, 160); however, differences
in sleep cycle patterns and distinct sleep phenotypes suggest that
ME/CFS and primary sleep disorders are, in fact, different entities
(167, 168) with many PWME showing normal sleep study results
(169). Primary sleep disturbances are considered exclusionary
for ME/CFS by a number of diagnostic criteria (101, 102, 160),
however, with little evidence that treatment of these disorders
improves symptoms of ME/CFS it is argued they are better
considered as comorbid conditions (2, 34, 170).
Also highly prevalent in those with ME/CFS is orthostatic
intolerance (OI), a common multifactorial disorder commonly
accompanying neurodegenerative, cardiovascular, metabolic,
and renal disorders (171). Disruptions to ANS and reduced
blood volume contribute to OI (172) and the same systemic
dysfunctions have been reported in those with ME/CFS
(51); however, not all people with OI disorders have
ME/CFS (173, 174).
Intestinal dysbiosis thought to be associated with some CNS-
related disorders via the gut-brain-axis (175). IBS is another
largely overlapping syndrome with both ME/CFS and FM but
metabolic profiles are distinct in ME/CFS and ME/CFS with
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FIGURE 2 | Hypothetical stages of disease in ME/CFS.
IBS subgroups (176). Some authors hypothesize IBS could be
considered an initial symptom of ME/CFS, as they reported
that 65% of IBS patients followed up developed ME (177).
Authors of a co-twin control study found significant associations
between CFS and FM, IBS, chronic pelvic pain, multiple chemical
sensitivities, and temporomandibular disorder. After controlling
for psychiatric risk factors, they argued that these associations
could not be attributed to uniquely psychiatric illness, thus
suggesting a “complex interplay of genes and environmental
factors” to help explain the clinical picture (178).
While healthcare costs likely increase following the diagnosis
of additional comorbidities (178), treating comorbidities
may improve the quality of life of PWME (2) not only
symptomatically but also in what they might be able to contribute
to the economy. We argue that by using the proposed natural
history framework, how and when common comorbidities
develop in relation to ME/CFS may be highlighted, allowing
researchers, and clinicians to better tailor potential interventions
according to each phase, thus resulting in a more efficient
management of costs.
Research Implications
These distinct hypothetical stages may help explain the apparent
inconsistency of findings from ME/CFS studies, which likely
include cases at distinct stages of disease with potentially
diverse systems abnormalities. Hence, we consider that the
conceptual approach presented in this paper may help to
elucidate pathophysiological mechanisms that may be more
prominent at different stages of disease; and consequently, could
indicate potential target therapeutic approaches in future. We
argue that the different stages patients go through during the
course of the disease, their severity, and the presence and degree
of complications are key parameters for disease stratification.
Research leading to an understanding of what is occurring
during the first three stages of progression to ME/CFS is
greatly needed but requires the recruitment of individuals for
research at pre-illness stage. Such research could be invaluable to
understanding the biological mechanisms at play before, during
and after an insult, and research using proxy disease models
for ME/CFS (85) or follow up of patients after an acute viral
infection [e.g., mononucleosis (76) or more presently COVID-
19] could begin to address this knowledge gap. Electronic health
records could also be a valuable source of retrospective pre-illness
data in people with ME/CFS. Well-designed longitudinal studies,
with strict protocols, would help refine this attempted description
of the natural course of the ME/CFS, and the interpretation of
the findings.
CONCLUSIONS
The concept of the natural history of disease, common in the
field of public health and medicine, serves to frame a disease
according to how it progresses from a pre-illness stage to the
final disease outcome. Due to the lack of knowledge surrounding
the etiology of ME/CFS, the heterogeneous presentation of
symptoms and their severity, and the lack of a recognized and
validated biomarker to determine diagnosis, the natural history
of this disease has been hard to determine.While current research
efforts tend to group ME/CFS subtypes according to clusters of
symptoms, few studies have considered ME/CFS as a continuum.
Pathophysiological patterns and changes along and across
disease stages result in the expression of different, albeit
overlapping phenotypes as seen in the preliminary UKMEB
findings related to changes in cytokine levels and symptoms
scores with time of disease, reported here. Ignoring phenotype
temporal variation in ME/CFS may have an impact on the
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outputs and the interpretation of research investigating disease
mechanisms, pathways, and interventions.
This paper sought to provide a simple framework, similar to
those of other chronic diseases, in an effort to extend the temporal
perception of ME/CFS and better incorporate the less defined
pre-illness stages of the disease. We believe that by applying
this framework to ME/CFS research efforts could better elucidate
the pathophysiological mechanisms of the disease and identify
potential therapeutic targets at distinct stages.
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